MIND4-17 (0.1-2 μM; 24 hr) significantly and concentration-dependently increases the expression of the canonical ARE genes Nqo1, Hmox1, Srx1, and to a lesser degree Gclc[1].
MIND4-17 (0.1-2 μM; 24 hr) shows a concentration-dependent induction of NQO1 and GCLM proteins in both WT and HD mutant ST14A cells[1].
MIN4-17 (0.1-10 μM) reduces ROS levels and nitrogen intermediates production in microglia[1].
MIND4‐17 (2 mg/kg; intravitreal injection; once) activates Nrf2 signaling and attenuates retinal dysfunction by light damage in mice[2].
References:
[1]. Luisa Quinti, et al. SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models. Cell Chem Biol. 2016 Jul 21;23(7):849-861.
[2]. Nan Chen, et al. The Nrf2 activator MIND4-17 protects retinal ganglion cells from high glucose-induced oxidative injury. J Cell Physiol. 2020 Oct;235(10):7204-7213.
















